Extension Study of MT-1303 in Subjects With Crohn's Disease
NCT02389790
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
MT-1303
Sponsor
Tanabe Pharma Corporation